Drugs / HS269
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05058352 | Oct 2021 → Oct 2022 | neoplasm | Zhejiang Hisun Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS269 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05058352 ↗ |
| Action | Inhibit | “RET Inhibitor” NCT05058352 ↗ |
| Modality | Small molecule | “a small molecule highly-selective RET Inhibitor” NCT05058352 ↗ |
| Route | Oral | “Oral tablets, once daily.” NCT05058352 ↗ |
| Target | RET | “RET Inhibitor” NCT05058352 ↗ |